Stanford-Lucidify EEG Delirium Study
This study is looking at how well a portable brainwave monitor, called the CGX EEG system, along with special software called Lucidify, can detect delirium (a state of severe confusion) in patients. The goal is to find delirium early to help reduce its harmful effects. You might be able to join if you are 55 or older, are suspected of having delirium or are at risk for it, are in the ICU or oncology ward at Stanford Medical Center, and speak English. The study will measure how accurately the CGX EEG/Lucidify system diagnoses delirium, tracks its development, and helps understand different types of delirium. The study is currently unclear on its recruitment status and plans to enroll 80 participants.
- Study design
- This is an observational study, meaning participants will be monitored without receiving a new treatment. It plans to include 80 participants.
- What's involved
- You would undergo monitoring via a portable EEG device for a minimum of 3 days up to a maximum of 7 days after joining the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be monitored from enrollment to the end of the study period, which is a maximum of 7 days post-enrollment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Stanford-Lucidify EEG Delirium Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- José R Maldonado, M.D. · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of subjects with delirium accurately diagnosed by the CGX EEG/Lucidify System24-hours a day monitoring for a minimum of 3 days from enrollment to the end of the study period (maximum of 7 days post-enrollment)
Record and collect EEG brain waves on study subjects using the CGX EEG/Lucidify System to assess EEG features to differentiate between delirium positive and delirium negative patients.
- Development of DeliriumFrom enrollment to the end of the study period (maximum of 7 days post-enrollment)
Number of subjects diagnosed with delirium
- Determination of Delirium PhenotypeFrom enrollment to the end of the study period (maximum of 7 days post-enrollment)
For those who develop delirium, the phenotype of delirium will be determined as per the Liptzin-Levkoff Criteria (based on DSM diagnostic Criteria). As such, all delirium episodes will be categorized as: hyperactive, hypoactive, mixed, or subsyndromal delirium. In addition, this phenotype determination will be compared with the CGX/Lucidify EEG System accelerometer data to determine concordance between the two.